INTRODUCTION
Natalizumab (Tysabri ® , Biogen Idec) is a humanized monoclonal antibody, raised against human 4-integrin, which has been licensed as monotherapy for relapsingremitting multiple sclerosis (RRMS) in 2006. In Europe, natalizumab (NZ) has been approved as a second line immunomodulator (IMD) treatment for patients who do not respond to first line IMD, whereas in the USA it has been approved as a first line therapy for patients with highly active disease.
The approval was based on the results of two doubleblind placebo-controlled trials: the pivotal AFFIRM and the SENTINEL studies. The AFFIRM study compared Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com
Carvalho AT, et al. Multiple sclerosis treatment with natalizumab, Acta Med Port 2014 Jul-Aug;27(4): [437] [438] [439] [440] [441] [442] [443] NZ with placebo in patients who, for the most part, had not received prior MS therapy. 1 The SENTINEL study compared two groups of patients: one group was treated with NZ in monotherapy and the other group received NZ in combination with interferon 1a IM.
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As a whole, these studies have shown that NZ reduces the number of new or enlarging T2 hyperintense and gadolinium-enhancing magnetic resonance (MRI) lesions (80-90%), reduces the number of annualized relapses (81%) and reduces the risk of progression of disability in RRMS patients (64%) in two years.
3 Studies have also confirmed higher efficacy of NZ over interferon or glatiramer acetate in RRMS.
The SENTINEL study settled the first safety concerns about progressive multifocal leukoencephalopathy (PML). During this study, 3 cases were reported, leading to a temporary suspension of drug commercialization. Several post-marketing safety surveillance programs [the TOUCH study (in the USA and Canada), TYGRIS and TOP studies (in Europe)]
4 ensured the safety and, consequently, the reintroduction of NZ in monotherapy.
Tysabri ® RCM was updated after the identification of risk factors for PML (serum anti-JC virus positive antibodies, treatment longer than 2 years and previous immunosuppressant therapy). Therefore, indications were restricted to highly active RRMS patients.
Because patients enrolled in clinical trials are carefully selected and frequently evaluated, real-world data may not fit the results of clinical trials. Therefore, daily practice clinical setting is crucial. This fact explains the significant increasing of 'real-world' data in the last few years.
We intend to describe the patients' cohort treated with NZ, since 2007, in the MS Clinic of Centro Hospitalar São João, based on daily practice. Analyzed variables include demographic data, disease features and safety and efficacy of NZ.
MATERIAL AND METHODS
We have conducted a retrospective study concerning patients with RRMS diagnosis, who have been treated with NZ (at least one dose) from January 2007 to May 2013.
Information was gathered about: demographic data (sex and date of birth), baseline disease data (year of MS diagnosis, prior IMD treatments, prior Expanded Disability Status Scale (EDSS) score and annualized relapse rate (ARR), NZ treatment data (number of perfusions, adverse effects and reasons for treatment withdrawal), efficacy data (EDSS score at 12 and 24 months after treatment, and ARR after 12 and 24 months of treatment), data after treatment (number of relapses, time to develop relapses and therapeutic option) and results of serology for JC virus DNA (STRATIFY test; first generation).
For statistical analysis, continuous variables were summarized using mean, standard deviation (SD) and median for, whereas categorical variables were summarized using absolute and relative frequencies. In order to compare ARR and EDSS before and after NZ, we used the T-student test, considering a significance level of 5%. According to Central Limit Theorem (which states that the arithmetic mean of a sufficiently large number of iterates of independent random variables, will be approximately normally distributed), we assume that this population has a statistically normal distribution.
RESULTS

Demographic characterization
We have found 66 patients treated with NZ since 2007 in our center. The majority [43/66 (65.2%)] were female, with a mean age of 35 years at the beginning of the treatment (range 14-64) and a mean disease duration of 9.5 years (range 1-38).
MS history (Table 1)
The most frequent clinical MS presentation was a brainstem syndrome [18/66 (27.3%)], followed by optic neuritis [12/66 (18.2%)]. The median baseline EDSS score was 4.0 (mean 3.8, range 0-7.5, n = 59). Twelve patients had EDSS lower than 2.0; in thirtytwo patients, the EDSS ranged from 2.0 and 6.0, whereas fifteen patients had baseline EDSS above or equal to 6.0.
In the year prior to treatment with NZ, median ARR was 2.0 (range 0-7.0, mean 2.0).
Almost all patients [60/66 (90.9%)] had received a prior first line IMD therapy or an immunossupressant (IMS), up to a maximum of three drugs; from these, more than half [35/60 (58.3%)] had received only one previous drug, all IMDs; 21/60 (35.0%) had taken two previous drugs (20 IMDs and 1 IMS -mitoxantrone) and a minority [4/60 (6.7%)] had received a third drug prior to treatment with NZ (2 IMDs e 2 IMS -cyclophosphamide). A few patients [4/66 (6.1%)] were naïve for MS therapy.
NZ history
The reasons for starting NZ were lack of efficacy of first line IMD in the majority of cases (73.8%), intolerance in 6.6% (side effects of first line IMD, leading to patients' discontinuation) and both in 13.8% (Table 2 ). In the remaining (6.6%), NZ was the first drug due to aggressive disease (rapidly evolving severe RRMS defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI).
The mean time of exposure to NZ was 24 months (range 1-65); 31 patients (47.0%) had received NZ for a period exceeding 24 months (Fig. 1 ).
The number of new patients throughout the years was variable, increasing from 2007 (7 patients) to 2009 (16 patients) and then decreasing until 2013 (5 patients).
Inclusion of new patients was higher among those diagnosed between the years 2007 and 2009, accounting for 22.6% of the total included patients.
Effective number of patients per year on NZ (influenced not only by the ratio 'new patients/patients who stopped NZ', but also by the treatment duration) increased from 7 in 2007 to 34 in 2010. After that, the number remained stable, with 31 patients being on NZ during 2013 (Fig.1) .
Overall, the drug was discontinued in 40/66 patients 
Efficacy outcomes
For the 53 patients who have completed 12 months of treatment, the median ARR has decreased from 2.0 (in the year prior to treatment) to 0.01 (mean 0.04; -1.9 variation, p < 0.001). At 24 months of treatment, for the 38 patients still exposed, the median ARR has remained 0.0 (mean 0.17). It is worth of note that 34/38 (91%) of patients have been relapse-free 24 months after NZ.
The EDSS has decreased from a median baseline score of 4.0 (mean 3.8, n = 59) to 2.0 at 12 months (mean 3.0, n = 51) and 2.5 at 24 months (mean 3.1, n = 37). So, the mean difference of EDSS was -0.8 (95% CI, 0.43-1.14) 12 months after NZ treatment (p < 0.001) and -0.7 (95% CI, 0.45-1.70) 24 months after NZ treatment (p < 0.001) (Fig. 2) .
Twelve months after NZ, 24 of 57 patients (42.1%) have improved EDSS score (defined as a decrease of at least 1.0 point, in respect to the total EDSS score and not to any specific functional system contained in the scale). Thirty-two of them (56.1%) have remained stable (defined as a variation less than 1.0 point) and the remaining [1/57 (1.8%)] have got worse (defined as an increase of at least 1.0 point) ( Table 3 ).
Adverse effects (Table 2)
We have observed one case of PML in a positive JC virus patient, after twenty-one continuous monthly infusions, with good outcome (clinical details presented in Discussion).
Other adverse effects imposing NZ suspension have occurred in 4 patients: toxic hepatitis (1); disabling arthralgias (1) and allergic reactions (2) . No significant adverse effects related to perfusion itself have been registered.
Evolution after NZ
Treatment after NZ suspension has been variable. However, the patients have usually returned to a first line IMD (11/30) or they have switched to fingolimod (8/30). Monthly intravenous methylprednisolone (4/30) or human immunoglobulin (5/30), have been other options. For one patient, our choice was azathioprine, since he had a chronic inflammatory bowel disease, and the remaining is not taking any medication (Table 4) .
Mean ARR 12 months after stopping NZ was 0.53 (n = 17). In fact, 11/17 (64.7%) have had no relapses, 5/17 (29.4%) have had 1 relapse and the other patient have had 4 relapses. Mean time for relapses was 7.5 months (range 2-12 months).
DISCUSSION
Natalizumab is one of the most recent treatments for RRMS, and its effectiveness has being consistently proved. However, there are safety concerns (primarily regarding PML). In fact, regardless the safety tests before commercialization, some adverse effects may be only evident on post-marketing surveillance, when the drug is ubiquitous in a real-world setting. In general, our results fit those earlier reported in other post-marketing studies, regarding efficacy and safety. [5] [6] [7] [8] [9] [10] [11] Our data are also consistent with previous findings in terms of baseline patients' profile: age at NZ starting, ARR in the year prior to NZ and clinical MS form. [5] [6] [7] [8] [9] [10] [11] Exception for consistency with other previous findings is made for baseline EDSS and disease duration until NZ, both found to be higher in our study than others 'real-world' studies. [5] [6] [7] [8] [9] [10] [11] It's possible that patients were included too late in the disease evolution; it may be explained by some initial reluctance in NZ prescription, regarding safety concerns, namely PML. On the other hand, this may reflect initial expectations about a new treatment; in fact, when NZ was first licensed in Portugal, it was seen as a last 'hope' for some patients, who were later found to be in a progressive phase of disease. Our patient with the highest EDSS score (7.5) was a 42-year-old woman with a secondary progressive with relapses MS. Treatment decision was based on the ongoing relapses, regardless the treatment with two previous first line IMD and an IMS (cyclophosphamide). However, an effort has been made in our center to enroll patients on NZ earlier in the disease evolution, when inflammatory component is more active. This option seems reasonable, based on mechanism of action of NZ (antagonism of the 4 subunit of integrin, expressed on the surface of activated T-cells, reducing the inflammation).
12 Indeed, this is the current tendency, which may help to explain why we have observed a higher percentage of patients with NZ-mediated EDSS score improvement than those previously reported in other cohort studies 6 and post hoc analyses from the AFFIRM trial.
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Our youngest patient was a 14 years-old girl, making NZ an off-label treatment (authorized by Ethics Committee of Centro Hospitalar São João). Our option was based on the severity of the disease and on the inefficacy of other drugs. Indeed, she had had a brainstem syndrome when she was 11; at that time, MRI revealed multiple lesions (probably demyelinating in nature), and the cerebrospinal fluid (CSF) showed a positive pattern of oligoclonal bands. She totally recovered with methylprednisolone. However, in the next 12 months, she had 3 more relapses (2 long pathways and 1 brainstem syndrome). At that time she was sent to our Clinic; she was diagnosed with RRMS and treatment with interferon -1b was started. However, relapses continued to occur every other month. Plasma exchange and add-on IVIG were tried, but they were inefficacious, both clinically Revista Científica da Ordem dos Médicos www.actamedicaportuguesa.com and radiologically: the patient had more relapses, disability was increasing and MRI revealed multiple new gadoliniumenhancing lesions in the brain and in the spinal cord. So, after her parents' consent, we decided to escalate therapy, moving to NZ. In addition to stop having relapses, she partially recovered from disability (current EDSS = 2), without NZ-related side effects. Overall, NZ was well tolerated among our patients and most of the adverse effects were non-severe. The patient who developed a toxic hepatitis had started another drug (amantadine) some weeks before; therefore it remains the doubt about which drug was responsible for this reaction. However, there have been post-market reports of liver lesion in patients taking NZ. 16 Our case of PML occurred in a 32 year-old male patient, who had previously been treated with interferon -1b (no history of IMSs). He had started NZ in 2010 due to inefficacy of first line IMD. Serology for JC virus DNA was known to be positive in 2011, when the STRATIFY test has become available. After 21 consecutive monthly infusions, he has developed a left hemiparesis without cognitive or behavioral changes, raising the suspicion of a new relapse. Nevertheless, the progressive motor worsening and lack of improvement with methylprednisolone 1g/day for 8 days have lead to PML suspicion and immediate NZ suspension. An urgent brain MRI was highly suspicious for PML, revealing one new diffuse cortico-subcortical right frontal lesion with no gadolinium enhancement or mass effect. In spite of a first negative CSF analysis for JC virus DNA (412 copies/ml of JC virus DNA has been confirmed in a second CSF analysis), he was treated with plasma exchange for five consecutive days, then with methylprednisolone 1 g for 5 days followed by prednisolone 1 mg/Kg, oral tapering, and mirtazapine (45 mg/day). Patients' symptoms have progressively worsened and, since the PML diagnosis, four high-dose methylprednisolone pulses have been performed. Serial MRIs have remained stable until January 2013. At that time, a gadolinium-enhancement lesion was observed due to a late immune reconstitution inflammatory syndrome. This patient also has presented focal motor seizures, responsive to levetiracetam 2 g/day and clonazepam 4 mg/day. The neurological deficits are now stabilized (EDSS 5.5) nevertheless he is still being treated with prednisolone 40mg/day. We stress the good outcome of this patient, possibly related to a precocious PML clinical suspect and treatment. Despite the absence of specific recommendations for PML in NZ-treated patients, the therapeutic strategy -based on reports from other MS Centers and in the experience got with PML developed in the context of human immunodeficiency virus infectionhas revealed successful in this case (presented at Second International Porto MS Congress 2013). 17 We are aware that the lack of MRI data is a limitation of our study. Still, we have decided to not include it, given that MRI is not exclusively performed inside our hospital (which means different equipments and protocols), making the comparison between exams poorly feasible.
The retrospective design is another obvious limitation of our study. Yet, inherent systematic bias may have been limited since all the information was collected from medical records rather than from patient recall.
Finally, these 'real-world' studies, performed outside the controlled setting of clinical trials, are very informative and probably closer to the clinical practice.
CONCLUSION
In our series of patients treated with NZ, on an average time of 24 months, there was a statistically significant reduction in ARR (-2 relapses/year) and EDSS (-1 point). Adverse effects were uncommon, although we had a case of PML. Our study confirms the previous data on NZ safety and efficacy in the treatment of RRMS in daily clinical practice.
